MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies
April 08 2024 - 1:20PM
Business Wire
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage
biotechnology company and a leader in the development of Microbiome
Ecosystem TherapiesTM (MET) dedicated to enhancing survival for
patients with cancer, presented new in vitro data characterizing
the metabolites produced by MaaT034 and their impact on immune
modulation at the American Association for Cancer Research (AACR)
Annual Meeting 2024 in San Diego, California.
MaaT034, the first product from MaaT Pharma’s MET-C platform is
a ground-breaking full ecosystem synthetic microbiota product,
developed in combination with immune checkpoint inhibitors to
improve treatment efficacy in large market solid tumor indications.
The MET-C platform enables MaaT Pharma to produce microbiome
therapies at a large-scale to meet the needs of larger market
indications. The first-in-human study is expected to be initiated
in 2025.
The data published represents significant advancements in
understanding the mechanism of action (MoA) of co-cultured
microbiome therapies developed by MaaT Pharma, marking a major step
towards clinical evaluation. The results demonstrate that MaaT034
produced key metabolites, recognized as promoting gut barrier
restoration and modulating immune responses, such as Short-Chain
Fatty Acids (SCFA), secondary bile acids, and tryptophan
derivatives. These findings support the role of MaaT034 in gut
barrier repair and in T cell reactivation either in combination
with Nivolumab (anti-PD1) or with Atezolizumab (anti-PD-L1). By
enhancing gut barrier repair and modulating immune responses,
MaaT034 is expected to complement the action of these
immunotherapeutic agents, potentially improving their efficacy in
treating solid tumors cancer.
Data are currently being shared in a poster format at the
conference titled, “Evaluation of a new co-cultured microbiome
ecosystem therapy candidate (MaaT034) for clinical testing as
adjuvant/neoadjuvant to immune checkpoint inhibitors in solid
tumors.”
About MaaT Pharma
MaaT Pharma, a clinical-stage biotechnology company, has
established a complete approach to restoring patient-microbiome
symbiosis in oncology. Committed to treating cancer and
graft-versus-host disease (GvHD), a serious complication of
allogeneic stem cell transplantation, MaaT Pharma has launched, in
March 2022, an open-label, single-arm Phase 3 clinical trial in
patients with acute GvHD, following the achievement of its proof of
concept in a Phase 2 trial. Its powerful discovery and analysis
platform, gutPrint®, enables the identification of novel disease
targets, evaluation of drug candidates, and identification of
biomarkers for microbiome-related conditions. The company’s
Microbiome Ecosystem Therapies are produced through a standardized
cGMP manufacturing and quality control process to safely deliver
the full diversity of the microbiome in liquid and oral
formulations. MaaT Pharma benefits from the commitment of
world-leading scientists and established relationships with
regulators to support the integration of the use of microbiome
therapies in clinical practice. MaaT Pharma is listed on Euronext
Paris (ticker: MAAT).
Forward-looking Statements
All statements other than statements of historical fact included
in this press release about future events are subject to (i) change
without notice and (ii) factors beyond the Company’s control. These
statements may include, without limitation, any statements preceded
by, followed by or including words such as “target,” “believe,”
“expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,”
“project,” “will,” “can have,” “likely,” “should,” “would,” “could”
and other words and terms of similar meaning or the negative
thereof. Forward-looking statements are subject to inherent risks
and uncertainties beyond the Company’s control that could cause the
Company’s actual results or performance to be materially different
from the expected results or performance expressed or implied by
such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240408637675/en/
MaaT Pharma – Investor Relations Guilhaume DEBROAS, Ph.D.
Head of Investor Relations +33 6 16 48 92 50
invest@maat-pharma.com
MaaT Pharma – Media Relations Pauline RICHAUD Senior PR
& Corporate Communications Manager +33 6 14 06 45 92
media@maat-pharma.com
Trophic Communications – Corporate Communications Jacob
VERGHESE or Priscillia PERRIN +49 151 7441 6179 maat@trophic.eu
Maat Pharma (EU:MAAT)
Historical Stock Chart
From Apr 2024 to May 2024
Maat Pharma (EU:MAAT)
Historical Stock Chart
From May 2023 to May 2024